Welgene Biotech Co.,Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 10, 2021
Share
Welgene Biotech Co.,Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced sales was TWD 75.512 million compared to TWD 101.596 million a year ago. Operating income was TWD 7.163 million compared to TWD 11.074 million a year ago. Net income was TWD 5.774 million compared to TWD 9.272 million a year ago. Basic earnings per share from continuing operations was TWD 0.25 compared to TWD 0.45 a year ago. For the half year, sales was TWD 123.822 million compared to TWD 193.360 million a year ago. Operating income was TWD 2.504 million compared to TWD 15.818 million a year ago. Net income was TWD 242,000 compared to TWD 11.134 million a year ago. Basic earnings per share from continuing operations was TWD 0.01 compared to TWD 0.54 a year ago. Diluted earnings per share from continuing operations was TWD 0.01 compared to TWD 0.53 a year ago.
WELGENE BIOTECH CO., LTD. is a Taiwan-based company mainly engaged in the provision of genetic testing services and products. The company focuses on deoxyribonucleic acid (DNA) microarray, Next Generation Sequencing and real-time quantitative polymerase chain reaction (PCR) and other testing technologies, which used in school research units, hospitals and biotech companies. The Company is also engaged in the trading of medical equipment. The company mainly operates in two business segments, including Biotechnology Testing segment and Equipment Trading segment. The Company mainly operates in Taiwan market.
WELGENE BIOTECH CO.,LTD. 
